The information in this section is intended for visitors outside the United States.
Increasing routine HIV and Hepatitis C screening is essential to slowing and ultimately ending these epidemics in the United States. One in eight HIV-positive Americans do not know they are infected, 45% of those diagnosed with HIV remain out of care, and it is estimated that 50% of people infected with HCV remain undiagnosed. Routine screening integrates HIV and HCV testing into regular care in clinics, hospitals, and other health care settings to address undiagnosed infection and engage individuals in treatment.
Established in 2010, Gilead’s FOCUS program (Frontlines of Communities in the United States) partners with healthcare providers, government agencies, and community organizations to change the way healthcare institutions approach HIV and HCV testing, and develop replicable model programs that embody best practices in screening and linkage to care.
FOCUS aims to:
FOCUS works in 17 cities across the United States that are heavily impacted by HIV and HCV, including Atlanta, Baltimore, Baton Rouge, Chicago, Dallas, Detroit, Houston, Jackson, Jersey City, Los Angeles, Miami, New Orleans, New York, Newark, Oakland, Philadelphia, and Washington, D.C.
FOCUS’ 200 partners have integrated routine HIV screening into a range of healthcare settings, conducting nearly 2 million tests and identifying more than 14,000 positives. In 2014, 60 partner organizations across all FOCUS cities began incorporating HCV screening and have conducted more than 160,000 tests.
Download a detailed overview of Gilead’s FOCUS Program (PDF).